|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:accessories
|
multiple countries
|
|
gptkbp:approves
|
gptkb:Bahrain
gptkb:China
gptkb:United_Arab_Emirates
gptkb:historical_figure
|
|
gptkbp:average_temperature
|
2 to 8 degrees Celsius
|
|
gptkbp:clinical_trial
|
gptkb:Bangladesh
gptkb:Argentina
gptkb:Monarch
gptkb:Morocco
gptkb:Pakistan
gptkb:Peru
gptkb:Politician
gptkb:Serbia
gptkb:United_Arab_Emirates
gptkb:historical_figure
Phase III
|
|
gptkbp:developed_by
|
gptkb:China_National_Pharmaceutical_Group
|
|
gptkbp:distribution
|
global
|
|
gptkbp:dosage_form
|
2
two doses
3 to 4 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sinopharm vaccine
|
|
gptkbp:is_documented_in
|
gptkb:battle
|
|
gptkbp:is_effective_against
|
79%
|
|
gptkbp:is_vulnerable_to
|
international
strong
refrigerated
emergency use authorization
ongoing studies
reduces transmission
viral vector vaccine
reduces hospitalization
reduces severe disease
effective against variants
inactivated virus platform
|
|
gptkbp:manager
|
intramuscular
|
|
gptkbp:manufacturer
|
gptkb:Sinopharm
|
|
gptkbp:safety_features
|
generally safe
|
|
gptkbp:side_effect
|
fatigue
headache
fever
mild
injection site pain
|
|
gptkbp:target_audience
|
adults
elderly
healthcare workers
high-risk groups
|
|
gptkbp:targets
|
gptkb:COVID-19
|
|
gptkbp:type
|
inactivated virus vaccine
|
|
gptkbp:bfsParent
|
gptkb:COVID-19_pandemic_in_Iran
|
|
gptkbp:bfsLayer
|
6
|